Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) can be difficult to differentiate clinically due to overlapping symptoms. Subject classification in research studies is often based on clinical rather than pathological criteria which may mean some subjects are misdiagnosed and misclassified. Recently, methods measuring cortical thickness using magnetic resonance imaging (MRI) have been suggested to be effective in differentiating between clinically-defined AD and frontotemporal dementia (FTD) in addition to showing disease-related patterns of atrophy. In this study we used FreeSurfer, a freely-available and automated software tool, to measure cortical thickness in 28 pathologically-confirmed AD patients, of which 11 had a typical amnestic presentation and 17 an atypical presentation 
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Introduction
Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) are histopathologically distinct, with AD being characterized by the presence of extracellular amyloid plaques, intraneuronal neurofibrillary tangles and neuronal loss [1] , and FTLD by neuronal loss and the presence of non-AD histological pathology, most commonly either taupositive inclusions or ubiquitin-positive, TDP-43-positive inclusions [2] .
Clinically, patients with underlying AD and FTLD pathology may present with overlapping symptoms. Typically, patients with AD pathology present with amnestic symptoms which gradually progress to involve multiple cognitive domains [3] . However, an increasing number of studies stress the importance of 'atypical' forms of AD, i.e. dementia in which the underlying pathology is AD, but in which memory is not the primary deficit [4;5] . Some patients with AD pathology may present with visuospatial and visuoperceptual problems and are diagnosed with posterior cortical atrophy (PCA) [6] ; whilst others present with marked behavioural features (so called 'frontal-variant AD') [7;8] ; yet others have a predominantly language presentation which often has features of logopenic/phonological aphasia (LPA) [9] .
These atypical behavioural and language presentations of AD can be difficult to distinguish from patient with FTLD pathology.
Patients with underlying FTLD pathology may also present with a range of different clinical symptoms. The clinical heterogeneity of FTLD is enshrined in diagnostic criteria which explicitly describe different clinical subtypes or variants. Three main clinical syndromes are distinguished: behavioural variant frontotemporal dementia (bvFTD), semantic dementia (SD), and progressive non-fluent aphasia (PNFA); the latter two are often referred to as primary progressive aphasia (PPA) [10] .
In this study, the term frontotemporal dementia (FTD) refers to the clinical (frontotemporal) syndrome which includes both behavioural and language variants, whereas FTLD refers to the confirmation of tau-or ubiquitin-positive pathology. Furthermore, the term 'typical AD' -4 -refers to patients with a typical amnestic presentation of AD and underlying AD pathology, whereas 'atypical' AD in this study refers to patients with AD pathology but who had a clinical diagnosis of either FTD or PCA. Within this group, the term AD-FTD refers to those patients who presented with FTD symptoms (behavioural or language deficits) and yet had underlying AD pathology at autopsy.
A number of studies have used magnetic resonance imaging (MRI) to assess brain atrophy in these disorders [11;12] . These patterns of atrophy may aid diagnosis -in vivo an atrophy 'signature' in life may predict the underlying pathology [13] . In many research studies, however, autopsy confirmation is lacking and 'clinically diagnosed' patients are included.
Clinical prediction of histopathology is inevitably imperfect; more importantly there is a risk of circularity. Clinically diagnosed subjects reflect 'typical' presentations of these diseases as the purpose of clinical criteria is to describe the most typical presentations to reduce misdiagnosis.
We investigated atrophy patterns in patients with pathology confirmation including atypical and typical clinical presentations of AD and FTLD. We wished to incorporate non-amnestic presentations of AD including language and behavioural presentations which are more likely to overlap with FTLD in terms of atrophy. The aim of this study was to assess the commonality of cortical thickness patterns between patients with AD pathology who presented with either typical amnestic deficits or atypical non-amnestic deficits during life. We further investigated patients clinically diagnosed as FTD to assess whether there were differences in cortical atrophy patterns between those who were subsequently found to have AD pathology and those with FTLD pathology.
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Materials and Methods
Subjects
We initially selected 62 patients from a database of pathologically-confirmed cases: 32 individuals with a pathological diagnosis of AD and 30 subjects with pathologically-confirmed FTLD who had undergone volumetric MR imaging as part of their diagnostic work-up. Twentyfive healthy controls that had undergone MRI assessment were also included. All clinically affected subjects had attended the Specialist Cognitive Disorders Clinic at the National Hospital for Neurology and Neurosurgery, London, UK. Informed consent was obtained from all subjects and the study had local ethics committee approval. Some of these patients have been included in previous imaging studies [14] [15] [16] . All patients underwent comprehensive clinical assessment which included the mini-mental state examination (MMSE) [17] . We excluded subjects with mixed AD and dementia with Lewy body pathology.
Pathologically-confirmed AD subjects were divided into typical and atypical AD patients based on their clinical ante-mortem presentation. Typical AD patients were defined as those who presented with amnestic deficits during life, whereas atypical patients presented predominantly with language, behavioural or visuoperceptual and visuospatial deficits, accompanied by some degree of memory impairment at the time of scan ( Figure 1 ). After image processing, 11 subjects were excluded (see below). The study therefore included 28 AD patients, 23 with FTLD, and 25 controls: the demographics of the 76 subjects included are summarized in Table 1 . Of the 11 typical AD subjects, 10 had post-mortem and 1 had brain biopsy confirmation. All of these AD patients had been diagnosed ante-mortem with AD according to NINCDS-ADRDA criteria [3] . Of the 17 atypical AD subjects, 12 had post-mortem confirmation and 5 had biopsy confirmation. This group consisted of 9 patients who had a clinical diagnosis of PPA, 6 patients with PCA, and 2 patients with bvFTD ( Figure 1 ). Of the 23 pathologically-confirmed FTLD subjects, 20 had post-mortem confirmation and 3 had brain biopsy. The FTLD group comprised 10 tau-positive patients (5 bvFTD, 4 PNFA, 1 atypical SD) and 13 tau-negative, ubiquitin-positive patients (10 SD and 3 bvFTD). All FTLD subjects were clinically-diagnosed with FTD [10] . FreeSurfer processing stream were undertaken: a locally-generated brain mask was used for skull stripping and FreeSurfer ventricular segmentations were added to the white matter mask to improve cortical segmentation [19] .
All images were visually inspected and on average edited and re-run three times as suggested (http://surfer.nmr.mgh.harvard.edu/fswiki/FsTutorial/TroubleshootingData). At this stage, as mentioned above, four individuals with AD and seven with FTLD were excluded due to poor image quality causing poor segmentations.
Statistical analysis
Regional cortical thickness variations between the patient groups and the control group were assessed using a vertex-by-vertex general linear model (GLM), performed with the SurfStat software (http://www.stat.uchicago.edu/~worsley/surfstat/). Cortical thickness (C) was modelled as a function of group, controlling for age, gender and scanner by their inclusion as covariates. We used separate models for the two comparisons of interest.
Comparison 1 assessed cortical thickness in typical and atypical AD, and was modelled C = β 1 (controls) + β 2 (typical AD) + β 3 (atypical AD) + β 4 age + β 5 gender + β 6 scanner + ε (where ε is error), contrasting β 1 vs. β 2 (controls vs. typical AD), β 1 vs. β 3 (controls vs. atypical AD), and β 2 vs. β 3 (typical AD vs. atypical AD; see Figure 1 ). Contrasts were calculated using two-tailed t-tests.
Comparison 2 assessed cortical thickness in AD-FTD (including the clinically diagnosed PPA and bvFTD patients with AD pathology) vs. FTLD, and was modelled C = β 1 (controls) + β 2 (AD-FTD) + β 3 (FTLD) + β 4 age + β 5 gender + β 6 scanner + ε, contrasting β 1 vs. β 2 (controls vs.
AD-FTD), β 1 vs. β 3 (controls vs. FTLD), and β 2 vs. β 3 (AD-FTD vs. FTLD, see Figure 1 ). Maps were produced showing percentage differences in average cortical thickness and statistically significant differences with false discovery rate (FDR) correction at p<0.05 [20] . Intersection maps highlight regions which two patient groups compared with controls had in common. Subjects were represented as points in an n-dimensional space, where n=299881 is the total number of vertices in the cortical surface (including left and right hemispheres, but excluding the medial wall). SVMs identify an optimal separating hyperplane in this space such that subjects from each group lie as far as possible from the hyperplane, on opposite sides. Once the hyperplane has been defined scores can be generated by projecting the points onto the normal of the hyperplane; the direction of the normal can be visualised as an image, showing the relative weights and signs of vertices' contributions to the classifier scores. We use the C-SVM formulation, employing a two-level nested cross-validation to optimize the misclassification penalty parameter C using a leave-one-out procedure within the main leaveone-out loop [24] . This ensures an unbiased estimation of generalisation accuracy by leaving each scan in turn entirely out of the training procedure.
Results
Subjects
No significant differences across groups were found for gender, disease duration and time to death (Table 1) . Age difference across all groups was not significant, however, the atypical AD group was significantly younger than controls (p<0.05). MMSE scores across patient groups differed significantly (p<0.05) which was mainly driven by the high MMSE scores in the FTLD group which differed from the typical and atypical AD groups (p<0.001 and p<0.01 respectively). parietal lobe, precuneus, medial temporal lobe, and frontal pole ( Figure 5B ). In contrast, regions which contributed most towards a classification of FTLD were shown bilaterally in frontal lobe regions and the lateral temporal lobe. 
Discussion
We have described distinct patterns of cortical thinning in pathologically-confirmed AD and FTLD patients. Patients with AD pathology and a typical amnestic presentation during life showed reduced cortical thickness bilaterally in the medial temporal lobe, posterior cingulate gyrus, precuneus, posterior parietal regions, and frontal lobe. The association of an amnestic presentation of AD with medial temporal lobe atrophy was expected [11;25;26] . The finding of prominent thinning in the posterior cingulate cortex and precuneus concurs with increasing recognition that atrophy as well as hypometabolism in these regions is characteristic of AD [15;27] . However, frontal pole involvement was less expected.
A similar pattern of cortical thinning, compared with controls, was found in patients with AD pathology who had a different ante-mortem clinical diagnosis; however, thinning was less widespread. A direct comparison between these two patient groups revealed greater loss in and MMSE may suggest that these differences simply reflect severity differences. However, mean disease duration was almost identical between groups. Disease progression in typical and atypical forms of AD may vary which means that disease duration is not a very accurate marker of disease severity. MMSE is also an imperfect indicator of disease severity in dementias in which memory is not the primary deficit, and the high mean MMSE in atypical AD subjects is largely driven by the PCA subjects included.
The intersection analysis illustrates the commonality of cortical thinning in typical and atypical AD. Cortical thickness was reduced in both the typical and atypical AD groups, compared with controls, bilaterally in the medial temporal lobe, posterior cingulate gyrus, precuneus, posterior parietal lobe and frontal pole. Cortical thinning in these regions may indicate the presence of AD pathology irrespective of clinical presentation. Cortical thinning in the medial temporal lobe in typical and atypical AD is consistent with the presence of memory deficits at the time of scan in both groups. Our general AD-specific findings are in accordance with previous imaging studies which investigated differences in cortical thickness [11;12] and grey matter volume using voxel-based morphometry [28;29] in typical forms of AD.
A strong involvement of the posterior cingulate gyrus in AD has been shown in a number of structural [15;28;30;31] and functional imaging studies [32] . Most functional imaging studies (PET, SPECT and fMRI) have reported reduced activity in this region in early stages of the disease [33] [34] [35] . The regions showing reduced cortical thickness in pathologically-confirmed AD patients in our study are consistent with those associated with the 'default mode' network [36] . Our finding adds to the growing number of studies suggesting that functional imaging findings are not as dissociated from atrophy as was once thought; temporal associations, however, remain unclear [37] .
The involvement of the frontal lobe in AD, and more specifically of the prefrontal cortex and frontal pole, remains controversial. A number of studies have shown reduced cortical -15 -thickness [11;12] and grey matter volumes [28;29;38] in this region. However, a number of studies have failed to show involvement of any frontal areas (for an overview see [39] ). Our study with the advantage of pathology confirmation does support frontal pole atrophy in AD.
There is always the theoretical possibility that this could be an artefact of the analysis technique, however, after careful visual inspection of this area in each subject we could not see any signal drop off or any kind of fault in the FreeSurfer surfaces which would explain reduced cortical thickness in this region. One strength of this study is that all AD and FTLD cases had pathological confirmation. This is particularly important considering that the clinical diagnosis of possible or probable AD (i.e.
fulfilling NINCDS-ADRDA criteria) typically gives accuracies of approximately 90% [44] , and the Neary criteria have been shown to have similar accuracies [45] . Consequently, a number of individuals included in studies of AD and FTLD will inevitably have a different type of pathology (i.e. only 10% of clinically-diagnosed AD cases were found to have non-AD pathology at post mortem [44] ). A post-mortem study further revealed 30% of patients diagnosed with a language subtype of FTLD (i.e. PNFA, SD) had AD pathology [46] . It should be noted that in the current study clinical diagnoses were obtained retrospectively from a cohort of pathologically-confirmed AD cases. Since post mortem confirmation of disease is less likely to be requested for patients with a typical AD presentation, the proportion of atypical compared with typical AD patients in this study is larger than commonly seen in a clinic. Furthermore, the inclusion of only pathologically-confirmed cases inevitably limits subject numbers, reducing the power to detect differences between disease groups.
Pathology confirmation was not obtained for the whole control group and it may be that some controls had a neurological condition but were asymptomatic. This is, however, unlikely and would only have reduced our ability to detect differences.
Another limitation is the variety in image acquisition which has been shown to affect thickness measures [47] . We therefore adjusted for scanner type in our statistical models. It should also be noted that there was an imbalance in scanner type between groups, with scanner A being present only in the control and typical AD group. However, excluding subjects imaged using scanner A from the analysis gave very similar results. Our groups were matched for disease duration, but not for disease severity as measured by MMSE. As expected, MMSE scores varied significantly between individual groups owing to the weighting of questions towards memory and orientation. We further showed that lower cortical thickness in the posterior cingulate gyrus, medial temporal lobe, parietal lobe and frontal pole can be suggestive of AD pathology in patients with behavioural or language deficits. In contrast, lower cortical thickness in the anterior temporal lobe and frontal lobe regions is indicative of the presence of FTLD pathology in patients with a clinical presentation of FTLD.
